Introduction {#Sec1}
============

The loss of myocardial tissue after acute myocardial infarction (AMI) leads to impairment of myocardial contractile function and left ventricular (LV) remodeling \[[@CR1]\]. Although prompt reperfusion is highly recommended following AMI for attenuating myocardial damages, reperfusion itself could cause additional lethal injury. This adverse phenomenon known as ischemia--reperfusion injury contributes infarct size and LV remodeling \[[@CR2], [@CR3]\]. New strategies that directly target the reperfusion phase could improve subsequent outcome after AMI.

Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues \[[@CR4]--[@CR6]\]. Numerous experimental data had reported the cardioprotective effects of EPO in infarcted heart. In these investigations, EPO was associated with significant reduction of myocardial fibrosis and improvements in LV function that were partly attributed to its antiapoptotic and angiogenic properties \[[@CR7]--[@CR9]\]. These findings are not supported by recent clinical trials designed to investigate the efficacy of EPO in AMI patients \[[@CR10], [@CR11]\]. Administration of EPO is also associated with higher rates of adverse cardiovascular events in these trials \[[@CR10]\]. However, the percentage of anterior AMI is below 50% in these trials. Anterior AMI is more strongly affected by ischemia--reperfusion injury simply because it perfuses a larger myocardial territory. Moreover, **t**here has been no data about the effect of EPO on coronary microvascular dysfunction (CMD) in anterior AMI patients.

We aimed to assess the effect of a single intravenous bolus of EPO on CMD and myocardial viability in anterior AMI patients. We also evaluated the serial changes in CMD and cardiac remodeling in these patients.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

We had prospectively enrolled first-time anterior AMI patients between October 2012 and January 2014 at the Wakayama Medical University Hospital. To be included, the patients had to have a first-time AMI with achieving reperfusion of the left anterior descending (LAD) coronary artery within 24 h of symptom onset. Seventy-five patients with ≥ 2 grade Thrombosis In Myocardial Infarction (TIMI) flow after successful PCI were randomized into the EPO or control group. Exclusion criteria were persistent severe heart failure (Killip class III or IV), cardiogenic shock, previous MI, multivessel disease, age \> 85 years, blood pressure \> 140/90 mmHg at the time of administration of EPO, advanced renal (Cre ≥ 2 mg/dl) and hepatic (T-Bil ≥ 3 mg/dl) dysfunction, and a hematocrit level \> 55% in female or \> 60% in male patients after PCI. Among 75 patients referred for possible enrollment into this study, 14 were excluded: six had severe heart failure or cardiogenic shock and five were found to have a clinical history of prior myocardial infarction. Three patients were also excluded because of advanced renal failure. The remaining 61 patients fulfilled the study criteria.

Study Protocol {#Sec4}
--------------

The study was a prospective, randomized, single-blind, placebo-controlled single-center trial. All procedures performed in studies involving human participants were in accordance with the institutional ethics committee of Wakayama Medical University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Trial registration: The institutional ethics committee of Wakayama Medical University, identifier, 1125. The patients were randomized by a blinded independent statistician, and the study processes were not blinded after randomization. The patients in the EPO group received a single intravenous administration of 100 ml saline mixed with EPO 12,000 IU (epoetin-beta, Chugai Pharmaceutical, Japan) at the end of PCI. The patients in the control group were injected intravenously with 100 ml saline. All the patients were given heparin intravenously (10,000--15,000 U/day) according to the standard protocol. Optimal standard treatment included administration of β-blocker, angiotensin-converting enzyme inhibitor, angiotensin II blocker, calcium antagonist, aspirin, clopidogrel, and lipid-lowering therapy. Plasma levels of vascular endothelial growth factor (VEGF) were measured at 1 week after the administration of EPO. Delayed-enhanced cardiac magnetic resonance imaging (DEMRI) was performed at 1 week after AMI to assess the transmural extent of infarcted myocardium and infarct size. Two-dimensional and Doppler echocardiography was performed at 1 week, 1 month, and 8 months after AMI to assess serial changes in cardiac remodeling and CMD of the LAD. All patients underwent clinical follow-up visits every 3 months after enrollment and were assessed for clinical status, safety, adverse reactions, and medication.

Echocardiography {#Sec5}
----------------

Transthoracic echocardiography was performed using a Vivid E9 System (GE Healthcare, Horten, Norway) equipped with a 2.5-MHz transducer. Parasternal long- and short-axis views at the basal, midventricular, and apical levels, as well as three standard apical views, were acquired from three consecutive beats (frame rate: 56--92 frames/s). LV ejection fraction (EF) and left atrial (LA) volume were calculated by the biplane modified Simpson' s method. LV mass was estimated by the two-dimensional area-length method.

Coronary flow velocity reserve (CFVR) is dependent on the combined effects of epicardial coronary stenosis and microvascular dysfunction \[[@CR3], [@CR12], [@CR13]\]. For coronary flow study, we administered adenosine triphosphate (0.14 mg/kg/min) intravenously for 2 min after the baseline coronary flow velocity (CFV) of the LAD was recorded. This allowed us to obtain the peak flow response induced by coronary microvessel dilatation. During examination, blood pressure and heart rate were recorded every minute. CFVs were recorded at the baseline and during hyperemia and averaged over five cardiac cycles. CFVR was defined as the ratio of mean diastolic CFV during hyperemia to that at the baseline \[[@CR12], [@CR13]\]. All measurements were performed by the experienced investigator who was blinded to all other data using EchoPAC 6.1; GE Healthcare, Horten, Norway. To assess the reproducibility of CFVR, the CFV measurements at base and during hyperemia were repeated 1 day later in randomly assigned 20 patients. The intra- and interobserver variability for the CFVR measurement were 4.3 ± 3.5% and 4.2 ± 3.6%, respectively.

Delayed-enhanced Cardiac Magnetic Resonance Imaging {#Sec6}
---------------------------------------------------

Cardiac MRI were performed with a 1.5-T clinical scanner (Intera Achieva, Philips Medical Systems, Best, The Netherlands) equipped with a five-element cardiac phased-array coil for signal reception, as previously described \[[@CR14]\]. Breath-hold cine steady-state free precession images with a time resolution of 35 ms were acquired. Then, the late enhanced images were obtained by a breath-hold three-dimensional turbo gradient echo with inversion recovery. Ten minutes after intravenous injection of 0.1 mmol/kg Gd-DTPA (Magnevist, Schering AG, Berlin, Germany), contiguous short-axis slices and representative long-axis slices of the LV were obtained. Scan parameters were as follows: repetition time, 4.1 ms; echo time, 1.25 ms; flip angle, 15°; field of view, 350 × 350 mm; partial echo; matrix, 224 × 256; and spatial resolution, 1.56 × 2.24 × 10 mm^3^ reconstructed to 0.68 × 0.68 × 5 mm^3^. All images were acquired during breath-hold at end expiration. The inversion time was optimized (200 to 300 ms) to null the normal myocardium.

All analyses were performed using a dedicated cardiac software package (View Forum, Philips, The Netherlands) for further analysis as described previously \[[@CR14]\]. Myocardial segments were analyzed for the presence of hyperenhancement, defined after setting of the threshold of ≥ 5 standard deviations above the mean signal intensity of the remote, normal myocardium in the same slice by the software \[[@CR15]\]. Normal myocardium was defined by the absence of any regional contrast enhancement and the combination of normal regional wall thickening. Based on the extent of hyperenhancement, a hyperenhancement category was determined for each segment on a five-point scale: 0% hyperenhancement (grade 0), 1--25% hyperenhancement (grade 1), 26--50% hyperenhancement (grade 2), 51--75% hyperenhancement (grade 3), 76--100% hyperenhancement (grade 4) \[[@CR16]\]. Then, the total myocardial area and the contrast-enhanced area were traced manually. The total infarct size was calculated, which was defined as the percentage of contrast-enhanced area of the total myocardial area (Area~hyperenhancement~/Area~myocardium~ × 100). Microvascular obstruction (MVO) was defined as hypoenhanced regions within the hyperenhanced infarcted area and was included in the calculation of total infarct size \[[@CR3]\].

Statistical Analysis {#Sec7}
--------------------

All statistical analyses were performed using SPSS version 11.0.1 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as mean ± standard deviation, and differences between groups were compared with the Student's *t* test for normally distributed variables and the Mann--Whitney test for non-normally distributed variables. The Chi-square test was used for categorical variables and Fisher's exact test for categorical variables with low frequencies (expected cell count \< 5). Comparisons of the time course of the change between groups were performed using two-way ANOVA. Comparisons of other data between groups were performed using one-way ANOVA. If statistical significance was found for a group, a time effect, or a group-by-time interaction, further comparisons were made with Tukey--Kramer post hoc test between all possible pairs of two groups at individual time points. All tests were two-sided and values of *p* \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Patient Characteristics {#Sec9}
-----------------------

The clinical baseline characteristics of the 32 EPO and 29 control patients are shown in Table [1](#Tab1){ref-type="table"}. There was no significant difference between the groups in age, sex, incidence of coronary risk factors, re-perfusion time, door-to-balloon time, peak creatine kinase, infarct location, TIMI flow grade after PCI, and VEGF. A list of the medications at the onset of AMI is also shown in Table [1](#Tab1){ref-type="table"}. All the patients in both groups underwent successful implantation of drug eluting stents. There was no significant difference about concomitant therapy between the two groups.Table 1Baseline clinical characteristicsEPO (*n* = 32)Control (*n* = 29)*p* valueAge, years68 ± 1271 ± 110.309Men, *n* (%)26 (81%)23 (79%)0.849BMI, kg/m^2^23 ± 222 ± 30.212Diabetes mellitus, *n* (%)8 (25%)5 (17%)0.46Hypertension, *n* (%)21 (66%)16 (55%)0.404Hypercholesterolemia, *n* (%)12 (38%)6 (21%)0.151Re-perfusion time, min358 ± 239400 ± 2350.389Door to balloon time, min78 ± 1277 ± 110.431Peak creatine kinase, U/l2749 ± 19122233 ± 14800.261Infarct location Proximal left ascending descending artery, *n* (%)15 (47%)16 (55%)0.873Concomitant therapy, *n* (%) ACE-I/ARB9 (28%)9 (31%)0.804 Beta-receptor blockers2 (6%)1 (3%)0.537 Statin7 (22%)4 (14%)0.412TIMI flow grade after PCI 2/37/255/240.649Vascular endothelial growth factor (pg/ml)41 ± 2435 ± 270.222*ACE-I* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker, *TIMI* thrombolysis in myocardial infarction, *EPO* erythropoietin

Effect of EPO on Myocardial Viability {#Sec10}
-------------------------------------

The results of DEMRI at 1 week after AMI are shown in Table [2](#Tab2){ref-type="table"}. EPO group had a tendency of smaller transmural extent of infarction than that of control group (2.4 ± 1.2 and 2.9 ± 1.1, *p* = 0.063). There was no significant difference in infarct size and incidence of MVO between the two groups (Table [2](#Tab2){ref-type="table"}).Table 2Delayed-enhanced cardiac magnetic resonance imaging parametersEPO (*n* = 32)Control (*n* = 29)*p* valueInfarct size (%)19 ± 1216 ± 90.399Delayed enhancement category Grade 0, *n* (%)2 (6%)0 (0%) Grade 1, *n* (%)5 (16%)3 (10%) Grade 2, *n* (%)12 (37%)8 (28%) Grade 3, *n* (%)5 (16%)6 (21%) Grade 4, *n* (%)8 (25%)12 (41%) Average2.4 ± 1.22.9 ± 1.10.063 Microvascular obstruction, *n* (%)5 (16%)9 (31%)0.224*EPO* erythropoietin

Effect of EPO on Coronary Circulation {#Sec11}
-------------------------------------

Table [3](#Tab3){ref-type="table"} shows the result of Doppler echocardiographic measurements and patient's condition. Regarding hemodynamic measurements, there were no significant differences in heart rate and BP between the two groups and among three phases. Figure [1](#Fig1){ref-type="fig"} demonstrates the change of CFVR in the two groups. CFVR at 1 week after AMI was similar between the two groups (2.1 ± 0.5 and 1.9 ± 0.4, *p* = 0.122). Mean diastolic velocity during hyperemia and CFVR was gradually improved during follow-up period (Table [3](#Tab3){ref-type="table"}). CFVR at 1 and 8 months after AMI was significantly higher than those at 1 week in EPO and control groups (Fig. [1](#Fig1){ref-type="fig"}). CFVR at 8 months after AMI was significantly higher in EPO group (2.9 ± 0.6) than those of control group (2.6 ± 0.5, *p* = 0.039) (Fig. [1](#Fig1){ref-type="fig"}). Figure [2](#Fig2){ref-type="fig"} shows representative images of CFVR and DEMRI after AMI in patients with and without the administration of EPO.Table 3Doppler echocardiographic measurementsEPO (*n* = 32)Control (*n* = 29)Heart rate b.p.m. (Baseline/ATP infusion) 1 week65 ± 9/68 ± 1164 ± 10/66 ± 11 1 month67 ± 12/70 ± 1273 ± 21/68 ± 10 8 months64 ± 11/66 ± 1163 ± 10/65 ± 9Systolic blood pressure, mmHg (Baseline/ATP infusion) 1 week106 ± 15/105 ± 13111 ± 21/111 ± 20 1 month110 ± 17/108 ± 16115 ± 21/115 ± 20 8 months113 ± 17/111 ± 16118 ± 13/116 ± 13Diastolic blood pressure, mmHg (baseline/ATP infusion) 1 week59 ± 10/57 ± 1160 ± 13/60 ± 13 1 month61 ± 10/59 ± 963 ± 12/62 ± 12 8 months62 ± 11/61 ± 1065 ± 9/65 ± 9Mean diastolic velocity, cm/s (baseline/ATP infusion) 1 week20 ± 7/42 ± 1619 ± 7/37 ± 19 1 month18 ± 4/46 ± 1518 ± 5/47 ± 18 8 months17 ± 4/48 ± 1318 ± 5/46 ± 19Coronary flow velocity ratio 1 week2.1 ± 0.5^†§^1.9 ± 0.4^‡§^ 1 month2.6 ± 0.52.6 ± 0.5 8 months2.9 ± 0.6^¶^2.6 ± 0.5*ATP* adenosine triphosphate, *EPO* erythropoietin^†^*p* = 0.0002 versus 1 month, ^‡^*p* \< 0.0001 versus 1 months, ^§^*p* \< 0.0001 versus 8 months, ^¶^*p* = 0.039 versus control Fig. 1Serial changes in coronary flow velocity reserve (CFVR). CFVR at 1 and 8 months after AMI was significantly higher than those at 1 week in EPO and control groups. CFVR at 8 months after AMI was significantly higher in EPO group compared with control group. *CFVR* coronary flow velocity reserve, *EPO* erythropoietin Fig. 2Representative CFVR and delayed-enhanced cardiac magnetic resonance imaging (DEMRI) images. CFVR at 8 months and DEMRI at 1 week after AMI in patients with and without the administration of EPO. *EPO* erythropoietin, *CFVR* coronary flow velocity ratio, *DEMRI* delayed enhancement magnetic resonance imaging

Effect of EPO on Cardiac Remodeling {#Sec12}
-----------------------------------

The echocardiographic measurements of EPO and control groups are shown in Supplemental Table 1 and Fig. [3](#Fig3){ref-type="fig"}. LV diameter, volume, LVEF, LV mass index, and LA volume at 1 week after AMI were similar between the two groups. In EPO group, LVEF at 8 months after AMI (53 ± 7) was significantly higher than those at 1 week (48 ± 7, *p* = 0.041) (Fig. [3](#Fig3){ref-type="fig"}). LA volume at 8 months after AMI was significantly lower in EPO group (47 ± 11) than those of control group (65 ± 20, *p* = 0.004) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Serial changes in cardiac remodeling. **a** LVEDV, **b** LVESV, **c** LVEF, **d** LA volume. In EPO group, LVEF at 8 months after AMI was significantly higher than those at 1 week (**c**). LA volume at 8 months after AMI was significantly lower in EPO group than those of control group (**d**). *LVEDV* left ventricular end-diastolic volume, *LVESV* LV end-systolic volume, *LVEF* LV ejection fraction, *LA* left atrial

Safety Analysis {#Sec13}
---------------

Supplemental Table 2 lists the blood cell count in peripheral blood during follow-up period. The peak of RBC, Hb, Ht were at the onset of AMI. There was no significant difference between the two groups at the onset of AMI and any timing of follow-up. No patients had polycythemia in the present study.

Discussion {#Sec14}
==========

In the present study, anterior AMI patients with the administration of a single dose of 12,000 IU EPO after PCI had a tendency of smaller transmural extent of infarction in the acute phase. To the best of our knowledge, we have demonstrated for the first time a favorable effect of EPO on CMD and LA remodeling in the chronic phase of anterior AMI.

Comparison with Other Clinical Trials {#Sec15}
-------------------------------------

EPO has been shown to protect various tissues submitted to ischemia--reperfusion in animal models, such as the brain, the retina, and the kidneys \[[@CR4]--[@CR6]\]. Several studies have also shown that administration of EPO during prolonged ischemia, or at the time of reperfusion, reduces infarct size and improves cardiac function in animal models of reperfused AMI \[[@CR7], [@CR8]\].

On the other hand, two recent clinical trials that have a significant sample size have shown negative or inconclusive results in regard to the safety and efficacy of EPO in patients with AMI \[[@CR10], [@CR11]\]. The randomized, double-blind, placebo-controlled REVIVAL trial showed that short-term high-dose EPO (60,000 IU of epoetin alfa) in timely reperfused myocardium does not reduce infarct size and does not improve LVEF \[[@CR10]\]. Small areas at risk in these clinical trials might be an issue for not showing an EPO beneficiary effect on the primary endpoint. Anterior AMI is more strongly affected by ischemia--reperfusion injury simply because it perfuses a larger myocardial territory. While the proportion of the patients with an occluded LAD were 27.6 and 40.9% in two clinical trials, we included the patients that occluded only LAD \[[@CR10], [@CR11]\]. Another clinical trial reported that EPO administration significantly improved LVEF in the LAD subgroup, although no significant difference was observed in direct comparisons of the EPO and control group \[[@CR17]\].

The REVIVAL trial also raised safety concerns due to a trend towards a higher incidence of adverse clinical events as well as an increase in neointima formation after treatment with EPO \[[@CR10]\]. A high dose of EPO may induce thrombocytosis and platelet activation, which increases the risk of thrombosis and cardiovascular events as a result. On the other hand, a single medium dose (12,000 IU) of recombinant human EPO has been widely used for dialysis patients safely. A single dose of 12,000 IU EPO did not promote polycythemia in a past human study \[[@CR17]\]. In the present study, we adopted a single dose of 12,000 IU EPO to avoid possible promotion of vascular events in the brain and heart. Therefore, our results indicate that the current safety concerns about EPO could not be translated to single medium dose administration in AMI patients treated with primary PCI.

Cardioprotective Effect of EPO in AMI {#Sec16}
-------------------------------------

There are two possible mechanisms to explain the cardioprotective effects of EPO. Firstly, stimulation of the EPO receptor in the heart augments neovascularization through the increase of VEGF and endothelial progenitor cells homing to the myocardium \[[@CR18]\]. Secondly, EPO has suppressive effects on apoptosis in ischemia--reperfusion models, potentially leading to smaller infarct sizes \[[@CR7], [@CR8], [@CR19]\]. In the present study, there was no significant difference in VEGF, incidence of MVO, and CFVR at 1 week after ant AMI between two groups. On the other hand, transmural extent of infarction had a tendency to be smaller in the EPO group. A strong correlation between the transmural extent of infarction and the recovery of regional function after AMI has been described \[[@CR20]\]. Indeed, time-dependent improvement of LVEF was observed only in the EPO group. Furthermore, CFVR at 8 months after AMI in EPO group was significantly higher than that of the control group.

CFVR is affected by the functional status of the distal microvascular bed in the absence of obstructive coronary artery narrowing and depends on multiple factors, including metabolic demands, myocardial resistance, filling pressures, neurohormonal activation, and vascular resistance of large and small coronary arteries \[[@CR21]\]. Some studies have indicated that CFVR in the LAD using transthoracic Doppler echocardiography accurately reflects invasive measurement using Doppler guide wire \[[@CR22], [@CR23]\]. Previous studies have reported that regional LV dysfunction correlated with impaired CFVR \[[@CR24]\]. Doppler flow studies with serial measurements of coronary flow observed an increase in CFVR, indicating recovery of myocardial microcirculation \[[@CR25]\]. Others also reported that improvement in CFVR was noted earlier than recovery of LV systolic dysfunction \[[@CR26]\]. In the present study, improvement in CFVR correlated with the recovery of LV systolic dysfunction in both groups. Although there was no significant difference in LVEF between the two groups in each time point, time-dependent improvement of LVEF was observed only in EPO group. Moreover, a single medium dose of EPO had a preventive effect on LA remodeling in chronic phase of anterior AMI. LA remodeling is an independent predictor of death or heart failure hospitalization after AMI \[[@CR27]\]. Furthermore, changes in LA size are related to worsening in increasing in LV volumes \[[@CR28]\].

In the present study, small transmural extent of infarction may contribute to improve CMD in the chronic phase. Several studies have shown that CMD assessed by CFVR can predict cardiac remodeling, and long-term cardiovascular events in AMI \[[@CR13], [@CR21]\]. Indeed, improvement of CMD in the EPO group may prevent LA remodeling in this study.

Limitations {#Sec17}
-----------

Our study has several limitations. First, the study did not provide the etiology of the improvement of transmural extent of infarction and CFVR. We did not provide the markers of apoptosis, inflammation, and fibrosis in each time point. Secondly, the study did not provide the findings of non-LAD AMI. Further studies are needed to compare LAD and non-LAD AMI using our protocol. Third, the data of our study were not the latest. Our study was completed in September of 2014. Finally, the study did not provide the clinical relevance. However, EPO could have a favorable effect on infarct size in the acute phase and on LA remodeling in the chronic phase of anterior AMI. Further studies are needed to assess the clinical endpoint in adequate sample size or the effectiveness of EPO in patients in poor condition such as heart failure.

Conclusions {#Sec18}
===========

In this prospective, randomized, single-blind, placebo-controlled trial, a single medium dose of EPO could have a favorable effect on CMD and LA remodeling in the chronic phase of anterior AMI. Our data suggest that a single medium dose of EPO administration would be a promising treatment for anterior AMI.
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